The common medication of menopause can prevent breast cancer while treating the hot flats

A medication aimed at treating the symptoms of menopause could be doubled as breast cancer prevention.

A new investigation of the Northwestern University in Illinois found that Duavee, a medication made by Pfizer, “significantly reduced the growth of breast tissue cells”, which is an important indicator of cancer progression.

A phase 2 clinical trial included 141 postmenopausal women who had been diagnosed with in situ ductal carcinoma (DCIS), also known as breast cancer in stadium 0, according to a press release from Northwestern.

Prostate cancer medication now available for more patients with an aggressive manner

This non -invasive breast cancer affects more than 60,000 American women every year, which often leads to a result of invasive breast cancer.

The women separated into two groups: one received Duavee and the other took a placebo for a month before undergoing breast surgery.

Duavee is a conjugated drug/bazedoxifen (CE/Bza) drug, which combines estrogen with another medication that minimizes possible harmful side effects of the hormone.

“The key conclusion of the study is that CE/Bza slows down the growth (proliferation) of cells in the DCIS milk ducts that expressed the estrogen receiver significantly more than the placebo,” said Dr. Swati Kulkarni, principal researcher and professor of breast surgery at the Northwestern University Medicine School of Medicine Feinberg, said News Digital.

The experimental women’s cancer drug increases survival rates in a remarkable study

Another important finding is that the quality of life did not differ significantly between the two groups, but the patients who took the CE/Bza reported less stifling during the study, he said.

“This would be expected, since the medicine is approved by the FDA to treat the suffocation.”

“What excites me most is that a medication designed to help women feel better during menopause can also reduce their risk of invasive breast cancer.”

Kulkarni presented the study last week at the annual meeting of the American Society of Clinical Oncology (disgust) in Chicago.

The findings are preliminary and have not yet been published in a medical magazine.

“What excites me most is that a medicine designed to help women feel better during menopause can also reduce their risk of invasive breast cancer,” said the doctor, who is also a mother surgeon for medicine in the northwest.

According to Kulkarni, women who face a higher risk of breast cancer, including those who have experienced “high -risk injuries”, and also have menopausal symptoms, are more likely to benefit from the medication.

“These women are generally recommended against standard hormonal therapies, leaving them with few options for menopausal treatment,” the statement said.

Study limitations

The researchers said that these early results are “encouraged”, but more research is required before medications can be considered for approval as a breast cancer prevention mechanism.

Click here to get the News application

“Our findings suggest that CE/Bza can prevent breast cancer, but larger studies are needed with several years of follow -up before we know this safely,” Kulkarni told News Digital.

Dr. Sheheryar Kabraji, Chief of Medicine of Mama at the Integral Cancer Center of Roswell Park in Buffalo, New York, did not participate in the study, but commented on the findings.

“While it is intriguing, this study is highly preliminary, and more research will be needed before we can conclude that estrogen/bazedoxifen conjugate (CD/BZA), a commonly prescribed hormonal estrogen shape to address the symptoms of menopause, prevents invasive breast cancer or is effective for reducing cancer risk,” he told News Digital.

Click here to register in our health newsletter

Kabraji also pointed out that the study focused on reducing the levels of a specific protein, “which does not always predict a reduced recurrence of breast cancer.”

“This study did not directly show that CE/Bza treatment reduces the risk of DCIS recurrence or the development of invasive cancer,” he said.

“While it is intriguing, this study is very preliminary.”

“It is important, however, the patients who received this therapy did not experience worsening of the quality of life, and the improvement of vasomotor symptoms, such as suffocations, if it is effective in preventing breast cancer, CE/Bza, it is likely to have less side effects than current medications used for breast cancer prevention.”

For more health articles, visit www.Newsnews.com/health

The main researcher Kulkarni emphasized that this medicine is not for the treatment of invasive breast cancer or DCIS.

“At this time, we can say that women worried about their risk of developing breast cancer can consider this medicine to treat their menopausal symptoms,” he added.